Management of Stage III Non–Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update Clinical Insights
JCO Oncology Practice · 2025-04 · 21 (4) · 463-466
DOI: 10.1200/op-24-00784 ↗Kurz gefasst
Leitlinie in der Zeitschrift JCO Oncology Practice, 2025-04. Verfasst von Navneet Singh und 4 weiteren Autor:innen. Beteiligte Einrichtung: Postgraduate Institute of Medical Education & Research, Chandigarh, India. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 13 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Postgraduate Institute of Medical Education & Research, Chandigarh, India.
- Department of Medical Oncology Cantonal Hospital of St Gallen, St Gallen, Switzerland.
- University of Bern, Bern, Switzerland.
- University of California, San Francisco, CA.
- American Society of Clinical Oncology (ASCO), Alexandria, VA.
- University of California Davis Comprehensive Cancer Center, Sacramento, CA.
ORCID-Profile: Navneet Singh, Nofisat Ismaila
Zitieren
APA
Singh, N., Früh, M., Gubens, M. A., Ismaila, N., & Daly, M. E. (2025). Management of Stage III Non–Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update Clinical Insights. JCO Oncology Practice, 21(4), 463-466. https://doi.org/10.1200/op-24-00784
Vancouver
Singh N, Früh M, Gubens MA, Ismaila N, Daly ME. Management of Stage III Non–Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update Clinical Insights. JCO Oncology Practice. 2025;21(4):463-466. doi:10.1200/op-24-00784
BibTeX
@article{Singh2025,
author = {Singh, Navneet and Früh, Martin and Gubens, Matthew A and Ismaila, Nofisat and Daly, Megan E},
title = {Management of Stage III Non–Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update Clinical Insights},
journal = {JCO Oncology Practice},
year = {2025},
volume = {21},
number = {4},
pages = {463--466},
doi = {10.1200/op-24-00784}
}
EUVIMED